Company Profile
Duke Human Vaccine Institute
Company Overview
The Duke Human Vaccine Institute (DHVI) continues to lead with cutting edge vaccine research against infectious diseases that impact global health. The investigators at DHVI conduct basic and translational research to develop novel vaccines, therapeutics and diagnostics for diseases such as HIV-1, tuberculousis, influenza, malaria, ebola, and cytomegalovirus. Several DHVI investigator led basic science discoveries that are currently being produced in Good Manufacturing Practice (GMP) facilities for early phase vaccine trials.